二甲氨异莰 | 3570-07-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 二甲氨异莰
• 英文名称: 2-Dimethylamino-isocamphan
• 英文别名: 3-Dimethylamino-isocamphan；N,N-2,3,3-pentamethylbicyclo[2.2.1]heptan-2-amine；Dimecamine；N,N,2,3,3-pentamethylbicyclo[2.2.1]heptan-2-amine
• CAS: 3570-07-8
• 化学式: C₁₂H₂₃N
• mdl: MFCD00867427
• 分子量: 181.321
• InChiKey: QEYHZXNEIGHKAV-UHFFFAOYSA-N

物化性质

• 沸点：
  64.0-65.5 °C(Press: 0.4-0.5 Torr)
• 密度：
  0.91±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  美卡拉明	mecamylamine	60-40-2	C11H21N	167.294

反应信息

• 作为产物：
  描述：

  美卡拉明 、 碘甲烷 以35%的产率得到
  参考文献：
  名称：

  SUCHOCKI, JOHN A.;MAY, EVERETTE L.;MARTIN, THOMAS J.;GEORGE, CLIFFORD;MAR+, J. MED. CHEM., 34,(1991) N, C. 1003-1010

  摘要：

  DOI：

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• 3, 4-dihydro-2(IH)-quinolinone and 2(1H)-quinolinone derivatives
  申请人：Tung Roger

  公开号：US20080103154A1

  公开（公告）日：2008-05-01

  The present invention relates to novel 3,4-dihydro-2(1H)-quinolinone and 2(1H)-quinolinone derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by atypical antipsychotic agents. The invention further provides methods for using a compound of this invention to determine concentrations of a corresponding 3,4-dihydro-2(1H)-quinolinone or 2(1H)-quinolinone compound, particularly in biological fluids, and to determine metabolism patterns of that 3,4-dihydro-2(1H)-quinolinone or 2(1H)-quinolinone compound.

  本发明涉及新颖的3,4-二氢-2(1H)-喹啉酮和2(1H)-喹啉酮衍生物，它们的可接受酸盐、溶剂化合物、水合物和多晶体。本发明还提供了包含该发明化合物的组合物，并将这些组合物用于治疗通过非典型抗精神病药物有益治疗的疾病和症状的方法。本发明还提供了使用本发明化合物测定相应的3,4-二氢-2(1H)-喹啉酮或2(1H)-喹啉酮化合物的浓度，特别是在生物液体中，以及确定该3,4-二氢-2(1H)-喹啉酮或2(1H)-喹啉酮化合物的代谢模式的方法。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• SUCHOCKI, JOHN A.;MAY, EVERETTE L.;MARTIN, THOMAS J.;GEORGE, CLIFFORD;MAR+, J. MED. CHEM., 34,(1991) N, C. 1003-1010
  作者：SUCHOCKI, JOHN A.、MAY, EVERETTE L.、MARTIN, THOMAS J.、GEORGE, CLIFFORD、MAR+

  DOI：——

  日期：——
• LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
  申请人：Scidose, Llc

  公开号：EP1954244A1

  公开（公告）日：2008-08-13